Related by context. All words. (Click for frequent words.) 85 Meets Primary Endpoint 83 Clinical Trial Results 83 Phase 2b Clinical Trial 82 Submits NDA 82 Osteoporosis Drug 82 Drug Candidate 82 Phase III Trial 81 Phase IIb Trial 81 Completes Patient Enrollment 81 FDA Accepts 81 Initiates Phase III 81 Receives Orphan Drug Designation 80 Phase III Clinical Trial 80 Patient Enrollment 80 Pivotal Phase III 80 Well Tolerated 80 Improves Survival 80 Presents Positive 80 JAK Inhibitor 80 Phase IIb Clinical Trial 80 Investigational Drug 80 Receives Approvable Letter 80 Demonstrates Potent 79 Survival Benefit 79 Previously Treated 79 Antitumor Activity 79 Gout Drug 79 Completes Enrollment 79 Study Showed 79 Present Preclinical Data 79 Epilepsy Drug 79 Cholesterol Lowering Drug 79 Drug Fails 79 Arthritis Drug 79 Investigational Treatment 79 Prolongs Survival 78 Lung Cancer Drug 78 Granted Orphan Drug 78 Mylan Receives Approval 78 Phase III Trials 78 Phase 2b Trial 78 Initiates Clinical 78 Presents Preclinical Data 78 Migraine Drug 78 Novel Antibiotic 78 Initiates Clinical Trial 78 Vaccine Adjuvant 78 Generic Version 78 Advanced Melanoma 78 Files IND 78 Investigational Agent 78 Phase 2a Clinical Trial 78 Initiates Phase II 78 Single Dose 78 Novel Oral 78 Schizophrenia Drug 78 Tezampanel 78 Shows Efficacy 78 Patients Treated With 78 Pivotal Study 78 Newly Diagnosed Multiple Myeloma 78 NDA Submission 78 FDA Approvals 78 Combination Treatment 78 Drug Shows Promise 78 Preclinical Data 78 Cholesterol Drug 77 Demonstrated Significant 77 Phase 2a Trial 77 Demonstrates Efficacy 77 Initiates Clinical Trials 77 Antidepressant Drug 77 Lupus Drug 77 Transdermal Patch 77 FDA Okays 77 Long Term Efficacy 77 Shows Promising 77 Pooled Analysis 77 Extended Release 77 Demonstrates Significant 77 Psoriasis Drug 77 Improved Survival 77 Presents Preclinical 77 Demonstrates Positive 77 Significantly Reduced 77 Recombinant Human 77 Receives Orphan Drug 77 Severe Sepsis 77 Fast Track Status 77 Improves Outcomes 77 Significantly Improved 76 Blood Thinner 76 Generic Versions 76 Patients Receiving 76 Anti Tumor 76 Preclinical Study 76 FDA Clears 76 Receives Positive Opinion 76 Low Dose 76 IND Application 76 Study Evaluating 76 Initiate Phase III 76 FDA Approves 76 Initiates Enrollment 76 Phase 2b Study 76 Protease Inhibitor 76 Adjuvant Treatment 76 Fixed Dose 76 Positive Opinion 76 Vildagliptin 76 Clinical Trial Evaluating 76 Renal Cell Carcinoma 76 Treated Patients 76 Oral Fingolimod 76 Pivotal Phase 76 Glatiramer Acetate 76 Expanded Indication 76 Prostate Cancer Vaccine 76 Announces Tentative Approval 76 Combination REOLYSIN R 76 Receives Fast Track 76 Hypertensive Patients 76 Pharmacokinetic Study 76 Controlled Trial 76 Phase IIa Clinical Trial 76 Inhaled Insulin 76 Pafuramidine 75 Teva Provides Update 75 Pivotal Trial 75 Previously Untreated 75 Blood Pressure Drug 75 Tiotropium 75 PRN FDA Approves 75 Statistically Significant 75 Effectively Treats 75 Anemia Drug 75 Initiate Clinical Trial 75 Files Investigational 75 Anti Tumor Activity 75 Diabetic Neuropathy 75 Diabetic Nephropathy 75 HCV Protease Inhibitor 75 Rheumatoid Arthritis Drug 75 Hypercholesterolemia 75 Vicriviroc 75 Receives Milestone Payment 75 Submits Supplemental 75 Phase 1b Clinical Trial 75 Adjunctive Therapy 75 Randomized Phase 75 Study Demonstrates 75 Chronic Hepatitis C 75 Rotavirus Vaccine 75 Initiate Phase 75 Medoxomil 75 Patients Treated 75 Treatment Naïve 75 Combination Therapy 75 Kinase Inhibitor 75 Generic Version Of 75 Hematological Malignancies 75 Rheumatoid Arthritis Patients 75 Overactive Bladder 75 Data Suggest 75 Begins Dosing 75 Significantly Improves 75 Oral Calcitonin 74 Monotherapy 74 Receives Tentative Approval 74 Phase III Clinical Trials 74 Mg Usa 74 Postmenopausal Osteoporosis 74 Hormone Refractory Prostate Cancer 74 Systemic Delivery 74 Trial Evaluating 74 Achieves Primary Endpoint 74 Clinical Trial Data 74 Bazedoxifene 74 Pivotal Trials 74 Successfully Completes Phase 74 Relapsing Multiple Sclerosis 74 Demonstrates Potential 74 Aliskiren 74 First Patient Enrolled 74 Milestone Payment 74 Unfractionated Heparin 74 Weight Loss Drug 74 Receives Complete Response 74 Anti Inflammatory 74 Febuxostat 74 Bosutinib 74 Oral Formulation 74 Intravenous Formulation 74 Refractory Hodgkin Lymphoma 74 Safinamide 74 Fungal Infections 74 Pulmonary Arterial Hypertension 74 Investigational Oral 74 Aflibercept 74 Placebo Controlled Trial 74 Elderly Patients 74 SPRYCEL ® 74 Fluconazole 74 Ambrisentan 74 Submits Biologics License Application 74 II Clinical Trial 74 Complicated Skin 74 Treatment Resistant 74 Effective Than 74 Myeloma Patients 74 Extended Release Formulation 74 Prostate Cancer Patients 74 Postmenopausal Women 74 PDUFA Date 74 Therapeutic Potential 74 Chronic Hepatitis B 74 Disease Progression 73 Oral Cladribine 73 Lupus Nephritis 73 IND Filing 73 Sapacitabine 73 Appears Safe 73 Benign Prostatic Hyperplasia 73 Dose Finding 73 Infected Patients 73 Hemodialysis Patients 73 Maleate 73 Inhaled Corticosteroids 73 Confirmatory Phase 73 Drug Combo 73 Dose Escalation 73 Drug Maker 73 Colorectal Cancer Patients 73 Novel Mechanism 73 Pazopanib 73 Erectile Dysfunction Drug 73 Efficacious 73 Orally Active 73 Cholesterol Drugs 73 Platelet Inhibition 73 Monoclonal Antibody 73 Versus Placebo 73 Nilotinib 73 Romidepsin 73 Kidney Transplant Patients 73 Double Blind Placebo 73 Autologous Stem Cell Transplantation 73 Metastatic Melanoma 73 Beneficial Effects 73 Adjuvant Therapy 73 Is Well Tolerated 73 Metastatic Colorectal Cancer 73 Nicotine Vaccine 73 Potent Antiviral Activity 73 Osteoporosis Treatment 73 Advanced Prostate Cancer 73 RNAi Therapeutic 73 Inhaled Liposomal Ciprofloxacin 73 Completes Dosing 73 Disease Modifying 73 HER2 Positive Breast Cancer 73 Mg Uk 73 Relapsed Multiple Myeloma 73 Randomized Double Blind 73 Tyrosine Kinase Inhibitor 73 Tolerability 73 Atypical Antipsychotic 73 Romiplostim 73 Hsp# Inhibitor 73 Golimumab 73 Vaginal Gel 73 Aztreonam Lysine 73 FDA APPROVES 73 Seasonal Influenza Vaccine 73 Partial Onset Seizures 73 Mouse Model 73 Antitumor 73 Montelukast 73 Reveals Positive 73 Treatment Naive Patients 73 Zoledronic Acid 73 Develop Novel 73 Lanthanum Carbonate 73 Heartburn Drugs 73 ANDA Filing 73 Boceprevir 73 Paliperidone Palmitate 73 Improve Survival 73 Multiple Myeloma Patients 73 Significantly Reduces 73 Anticancer Agent 73 Anticancer Drug 73 Supplemental Biologics License Application 73 Controlled Study 72 TNF Blockers 72 Epoetin Alfa 72 Lixisenatide 72 Tablet Formulation 72 BioSante Pharmaceuticals Announces 72 Lung Cancer Patients 72 Pediatric Patients 72 Patent Covering 72 R lenalidomide 72 Small Molecule 72 Hepatitis B Vaccine 72 Telbivudine 72 Ropinirole 72 sapropterin dihydrochloride 72 Cutaneous T 72 Slow Progression 72 Cardiovascular Events 72 Eszopiclone 72 Inflammatory Arthritis 72 Interferon Beta 72 Receptor Agonist 72 Adjuvant Chemotherapy 72 HER2 Positive 72 Capsules CII 72 Resistant Hypertension 72 First Patient Treated 72 RNAi Therapeutics 72 Dasatinib 72 Maribavir 72 Anticancer Activity 72 Receive Milestone Payment 72 Desloratadine 72 Cholesterol Lowering 72 Parathyroid Hormone 72 Plus Ribavirin 72 Initiates Phase 72 Kidney Transplant Recipients 72 Tumor Growth 72 Enoxaparin 72 Osteoporosis Drugs 72 Advanced Pancreatic Cancer 72 Venous Thromboembolism 72 Treatment Reduces 72 Treating Chronic 72 Launches Generic Version 72 Antipsychotic Drug 72 Statin Drugs 72 Oncology Compounds 72 Patients Suffering 72 Attenuates 72 Asthma Treatment 72 Therapy Improves 72 Sitagliptin 72 Tipranavir 72 Ranolazine 72 Novel Compound 72 Peginterferon Alfa 2a 72 Testosterone Gel 72 Reports Preclinical Data 72 Treatment Regimen 72 Fondaparinux 72 Recurrent Breast Cancer 72 Cethromycin 72 Dose Ranging Study 72 Aurora Kinase 72 Presents Positive Preclinical 72 Subgroup Analysis 72 Generic Lovenox 72 Combo Therapy 72 Autoimmune Disease 72 Prophylactic Treatment 72 Inhibits 72 VIVITROL ® 72 Hormone Therapy 72 Collaborators Present 72 Shows Promise 72 Inflammatory Markers 72 Xcytrin R 72 Desvenlafaxine 72 Novel Therapeutic 72 Therapeutic Efficacy 72 Knee Osteoarthritis 72 Antipsychotic 72 Extended Release Tablets 72 JAK2 Inhibitor 72 Phospholipase A2 72 Patient Enrolment 72 Randomized Clinical Trial 72 Telithromycin 72 Release Tablets 72 NICE Recommends 72 First Patient Dosed 72 Allergic Rhinitis 72 Heart Failure Patients 72 Shows Promise Against 72 Glucose Control 72 Pegylated 72 Increased Mortality 72 methylnaltrexone bromide 72 Pegloticase 72 Atypical Antipsychotics 72 Drug Coated Stent 72 Peginterferon 72 Atopic Dermatitis 72 Paclitaxel Carboplatin 72 Beta Blocker 72 Liver Damage 72 Advanced Colorectal Cancer 72 Muraglitazar 72 Protease Inhibitors 72 Secondary Hyperparathyroidism 72 Brentuximab Vedotin SGN 72 R memantine HCl 72 Plaque Psoriasis 72 Fracture Risk 71 Breast Cancer Recurrence 71 Epilepsy Drugs 71 Kidney Function 71 Glufosfamide 71 Optimer Pharma 71 STELARA TM 71 Clinical Outcome 71 Initiates Phase 2b 71 Ridaforolimus 71 adalimumab Humira 71 Eluting Stent 71 Extended Release Capsules 71 Meta Analysis 71 Brain Metastases 71 Receives FDA Clearance 71 Preclinical Models 71 Rivaroxaban 71 Monopril 71 Azacitidine 71 Bucindolol 71 oral prodrug 71 Randomized Double blind 71 Bone Fracture 71 Diet Pill 71 aripiprazole Abilify 71 Announces Publication 71 Vitro Activity 71 Reduces Risk 71 Patients Undergoing 71 Oral Insulin 71 MEK Inhibitor 71 Hydrochlorothiazide Tablets 71 Inhalation Aerosol 71 Confirms Efficacy 71 Proves Effective 71 Mycophenolate Mofetil 71 Lowers Risk 71 Neuroprotective Effects 71 Zileuton 71 Earns Milestone Payment 71 Chronic Constipation 71 Novel Inhibitor 71 Telaprevir VX 71 Tesamorelin 71 Hematological Cancers 71 Shown Effective 71 Zorbtive TM 71 Randomized Phase II 71 Melphalan 71 HDAC Inhibitor 71 Testosterone Patch 71 Clinical Efficacy 71 Lung Cancer Trial 71 Advanced Renal Cell 71 Anticancer Compound 71 Sustained Release 71 Zoloft sertraline 71 Immunomedics Announces 71 Fluticasone 71 Severe Asthma 71 Chemotherapeutic Agents 71 Submits Response 71 See CLINICAL PHARMACOLOGY 71 Fulvestrant 71 Cypher Sirolimus 71 TO AVOID PREGNANCY WHILE 71 Iloperidone 71 Gene Variant 71 Receptor Antagonist 71 Proven Effective 71 Drug Prevents 71 Hepatitis C Genotype 71 Antiviral Activity 71 Proton Pump Inhibitor 71 BioElectronics Announces 71 serotonin norepinephrine reuptake inhibitor 71 Anemia Drugs 71 Multicenter Trial 71 Hepatitis C Patients 71 Statin Therapy 71 Vitrasert R 71 Drug Resistant 71 Treatment Experienced 71 Tablets #mg [002] 71 Gets FDA Clearance 71 Treatment Shows Promise 71 Treatment Naive 71 Antiviral Drugs 71 Schizophrenia Treatment 71 Pivotal Clinical Trial 71 PEGylated Fab fragment 71 Soriatane 71 Biomarker Study 71 Patients Enrolled 71 Release Capsules 71 Sustained Reduction 71 Reduced Risk 71 Myelodysplastic Syndromes 71 Topline Results 71 Roche Boniva 71 Prospective Randomized 71 Spectrum Pharmaceuticals Announces 71 Psoriasis Patients 71 Valsartan 71 thalidomide Thalomid 71 Elagolix 71 Anticancer Drugs 71 Phase III Pivotal Trial 71 Randomized Study 71 Therapeutic Competitors Companies 71 Anti Inflammatory Drug 71 Breast Cancer Treatment 71 Aloxi ® 70 Bevacizumab 70 Efficacy Trial 70 BARACLUDE R 70 Diabetic Patients 70 Acute Heart Failure 70 Slows Progression 70 PEGylated anti 70 Myelodysplastic Syndrome MDS 70 Commences Phase 70 Antifungal 70 Phase III Pivotal 70 Announces FDA Clearance 70 Progressive Multifocal Leukoencephalopathy 70 Fluorouracil 70 pralatrexate injection folate analogue 70 Serious Side Effects 70 Lung Cancer Survival 70 ACE Inhibitors 70 ZOLINZA 70 FOLOTYN ® 70 Double Blind Randomized 70 Cetrorelix 70 Shingles Vaccine 70 rasagiline tablets 70 Collaborators Publish 70 Relapsed Refractory 70 Taro Receives 70 Topical Cream 70 Bivalirudin 70 Prostate Cancer Treatment 70 Personalized Immunotherapy 70 Insulin Glargine 70 Anti CD# Antibody 70 Interferon beta 1a 70 Submits IND 70 Dapagliflozin 70 Desvenlafaxine Succinate 70 Oral Contraceptive 70 Demonstrates Statistically Significant 70 Hospital Acquired Pneumonia 70 Emerging Therapies 70 Successfully Treated 70 Milestone Payment From 70 Cervical Cancer Vaccine 70 Placebo Controlled Study 70 Efficacy Results 70 ritonavir boosted 70 Newly Diagnosed 70 Lamotrigine 70 Hepatocellular Carcinoma 70 Renal Impairment 70 Million Milestone Payment 70 Acute Ischemic Stroke 70 Inhalation Solution 70 Showed Significant 70 Laquinimod 70 Abstract Accepted 70 Breast Cancer Cells 70 Gemcitabine 70 Fingolimod 70 DIRECT Trial 70 pioglitazone hydrochloride 70 Licenses Novel 70 Taxane 70 Immunotherapeutic 70 Etanercept 70 Nitazoxanide 70 investigational humanized monoclonal antibody 70 PharmaVitae Profile 70 Granulocyte Colony Stimulating Factor 70 Methylnaltrexone 70 Vaccine Candidate 70 Chronic Myeloid Leukemia 70 Cardiotoxicity 70 Topical Treatment 70 Node Positive 70 Increases Risk 70 Eltrombopag 70 Gastric Cancer 70 Migraine Treatment 70 Renal Cancer 70 Capecitabine 70 Bipolar Depression 70 Interferon Gamma 70 Milestone Payments 70 Boosts Survival 70 Actonel risedronate 70 FDA Panel Recommends 70 Trodusquemine MSI 70 Epratuzumab 70 Ziprasidone 70 Bronchodilator 70 Submits Application 70 Bare Metal Stents 70 Chronic Lymphocytic Leukemia 70 Nucleoside 70 Soft Tissue Sarcoma 70 Ozarelix 70 Acute Attacks 70 Pramlintide 70 Low Doses 70 Anthracycline 70 Metformin HCl 70 investigational oral inhibitor 70 Advanced Ovarian Cancer 70 Anti Clotting Drug 70 Stomach Cancer 70 Immune Responses 70 Naive Patients 70 Gene Therapy Trial 70 Metastatic Prostate Cancer 70 Vaccine Protects Against 70 R Saizen R 70 Immunosuppressant 70 Metabolic Disorder 70 Antibody Drug Conjugate 70 Mometasone Furoate 70 Darbepoetin Alfa 70 Therapeutic Competitors Report 70 Denufosol 70 Announces Poster Presentations 70 Polymerase Inhibitor 70 Sprycel dasatinib 70 Menopausal Women 70 Pharmacodynamics 70 Transdermal Delivery 70 VIVUS Announces 70 Regeneron Pharma 70 TNF Tumor Necrosis Factor 70 Ciclesonide 70 Fewer Side Effects 70 Cancidas 70 Phase 2a Study 70 Treatment Naïve Patients 70 Novel Treatments 70 Systemic Sclerosis 70 Initiates Dosing 70 Castration Resistant Prostate Cancer 70 orally administered inhibitor 70 Topical Gel 70 Phase IIa Trial 70 sertraline Zoloft 70 Sangamo BioSciences Announces 70 Pain Medications 70 Cardiovascular Outcomes 70 Announces Presentation 70 non nucleoside inhibitor 70 Onyx Pharmaceuticals Announces 70 Relapsing Remitting Multiple Sclerosis 70 Reduced Incidence 70 Pirfenidone 70 Oral Mucositis 70 Indacaterol 70 Breast Cancer Patients 70 Gene Linked 70 Smallpox Vaccine 70 Generic Protonix 70 Phase Ib Clinical Trial 70 Obese Patients 69 Carboplatin Paclitaxel 69 Premenopausal Women 69 Archexin 69 FDA Approvable Letter 69 Artery Disease 69 atazanavir sulfate 69 Civacir 69 Cell Transplants 69 Shows Statistically Significant 69 Copegus ® 69 Demonstrate Significant 69 Known hypersensitivity 69 Gastrointestinal Disorders 69 Recommends Approval 69 Therapeutic Competitors companiesandmarkets.com adEgemonye 69 Calcitonin 69 Vidaza azacitidine 69 Budesonide 69 Cinacalcet 69 Increased Risk 69 Tigecycline 69 Treat Anemia 69 Demonstrates Sustained 69 selective modulator 69 Synthetic Peptide 69 Suicidality 69 Factor Receptor 69 octreotide acetate 69 VIVUS Qnexa 69 Nymox NX 69 Enlarged Prostate 69 Dendritic Cells 69 1mg 2mg 69 Panzem R 69 Induces 69 Adenoma 69 Universal Flu Vaccine 69 Fludara ® 69 R pioglitazone HCl 69 Nasal Spray 69 alefacept 69 Dual Antiplatelet Therapy 69 Darinaparsin 69 Announces Initiation 69 Ecallantide 69 HIV treatments Reyataz 69 FDA Clearance 69 PKC# 69 ORENCIA ® 69 Pegylated Interferon 69 FDA Approves Drug 69 Gene Mutation 69 Antihypertensive 69 GATTEX TM 69 Oxybutynin 69 Tanespimycin 69 Crit Rev 69 Pharmacokinetics PK 69 Oral Anticoagulant 69 Lubiprostone 69 Microplasmin 69 HCl Injection 69 Levoleucovorin 69 Mesalamine 69 Gene Variation 69 Acute Pancreatitis 69 Inc Therapeutic Competitors 69 Adalimumab 69 Epidermal Growth Factor Receptor 69 lamotrigine Lamictal 69 Generalized Anxiety Disorder 69 Hepatic Encephalopathy 69 5 Fluorouracil 69 Clinical Study 69 Resubmission 69 2 methoxyestradiol 69 Miconazole 69 ONGLYZA TM 69 Predict Risk 69 Saxagliptin 69 sorafenib Nexavar 69 Horizant ™ 69 Subtypes 69 Receives Marketing Authorization 69 Moxifloxacin 69 Delayed Release 69 Long Term Survival 69 Submits Investigational 69 Intravitreal 69 R metformin Concor 69 Ticagrelor 69 oxaliplatin Eloxatin 69 J Am Coll 69 evaluating tivozanib 69 Drug Eluting 69 etanercept Enbrel 69 Study Indicates 69 Syncria R 69 Capoten 69 Study Confirms 69 Xibrom TM 69 Potentially Fatal 69 IL# PE#QQR 69 interferon gamma 1b 69 Eculizumab 69 abacavir sulfate lamivudine 69 Fabry Disease 69 Keryx Biopharma 69 Neoadjuvant Chemotherapy 69 Antigen Specific 69 pan HDAC inhibitor 69 Serious Infections 69 Temsirolimus 69 Atomoxetine 69 Study Proves 69 Camptosar ® 69 Valopicitabine 69 Pain Relievers 69 Dose Response 69 Bristol Myers Squibb Pravachol 69 Stem Cell Treatment 69 Arthritis Drugs 69 Diabetic Foot Ulcer 69 ergot derivatives 69 OSMOPREP TM 69 #-# Full Text 69 Pemetrexed 69 Tolvaptan 69 Omacetaxine 69 Mirapexin R 69 investigational pharmacologically unique 69 Cocaine Addiction 69 Hepatitis C Treatment 69 Posaconazole 69 Prodrug 69 Elevated Levels 69 Randomized Double Blind Placebo 69 Replacement Therapy 69 Levels Linked 69 Faropenem 69 Erlotinib 69 Stent Implantation 69 AAG geldanamycin analog 69 Oral Spray 69 Liver Transplant Patients 69 metformin HCl 69 miconazole Lauriad ® 69 Commonly Prescribed 69 Randomized Controlled 69 Toremifene 69 Cancer Treatments 69 Bipolar Mania 69 Humanized Anti 69 Ovitrelle R Serostim 69 CYP#A# CYP#D# 69 Interferon Alpha 69 gets USFDA nod 69 Treatment Naive HIV 69 Test Detects 69 Novel Compounds 69 Itraconazole 69 Danazol 69 Liprotamase 69 Sumatriptan Succinate 69 Darunavir 69 Therapeutic Antibody 69 SUTENT ® 69 Chronic Sinusitis 69 albiglutide 69 Randomized Trials 69 Daptomycin 69 Peginterferon alfa 2b 69 Kuvan R 69 Menopausal Symptoms 69 Seasonal Allergic Rhinitis 69 Poorly Controlled 69 LibiGel ® 68 Dupuytren Contracture 68 Liver Failure 68 Hormone Receptor Positive 68 Antiplatelet 68 RhuDex 68 Doripenem 68 panitumumab Vectibix 68 Ovarian Cancer Patients 68 R bisoprolol Euthyrox 68 Integrase Inhibitor 68 Genes Linked 68 Abiraterone Acetate 68 candesartan cilexetil 68 Ustekinumab 68 Sagent Pharmaceuticals Announces 68 administered concomitantly 68 Non Responders 68 virus HCV protease inhibitor 68 venlafaxine Effexor 68 Remicade infliximab 68 Insulin Resistance 68 Biogen Genentech 68 Peginterferon Alfa 2b 68 XYOTAX TM 68 Decitabine 68 ThermoDox R 68 Pralatrexate 68 Anti Nausea 68 Orthostatic Hypotension 68 Hepatitis C Virus 68 Arimoclomol 68 GRAS Status 68 Bisphosphonate 68 MKC# MT 68 monoclonal antibody conjugated 68 Invasive Breast Cancer 68 Skeletal Muscle 68 Stent Restenosis 68 cardiometabolic diseases Glucophage 68 Inhaled Nitric Oxide 68 MAGE A3 ASCI 68 Pravastatin 68 Sipuleucel T 68 Amlodipine Besylate 68 Inflammatory Diseases 68 Septic Shock 68 Chemotherapy Regimen 68 Carbidopa Levodopa 68 Completes Patient Enrolment 68 Hepatotoxicity 68 vapreotide acetate 68 ORENCIA R 68 Acetate Rectal Suppositories 68 Critically Ill Patients 68 beta 1a 68 SAR# [002] 68 FDA Warns 68 Transdermal System 68 paroxetine sertraline 68 Clostridium difficile Infection 68 Immune Cells 68 Antiangiogenic 68 CYPHER R Sirolimus Eluting 68 Drug Coated Stents 68 MKC# MKC# PP 68 Liver Toxicity 68 docetaxel Taxotere ® 68 Antisense Drug 68 ribavirin USP 68 Risedronate 68 dasatinib Sprycel ® 68 Predict Response 68 candidates Azedra 68 Endometrial Cancer 68 hydrochloride tablets 68 Reduces Mortality 68 Avanafil 68 Protein Linked 68 Chemoradiation 68 developing Bicifadine serotonin 68 Autoimmune Diseases 68 Boxed Warnings 68 Diagnostic Tests 68 Xeloda ® 68 Formoterol 68 Mimetics 68 Bepreve TM 68 Heart Stents 68 pregabalin Lyrica 68 ziprasidone Geodon 68 ALN HPN 68 Venlafaxine 68 Renal Anemia 68 Inflammatory Disease 68 Pharmacyclics Announces 68 Immunosuppression 68 Vidaza R 68 Fenofibrate 68 Ethinyl Estradiol 68 Tuberculosis Vaccine 68 AZILECT R 68 Receives SFDA Approval 68 AVAPRO 68 ISTODAX ® 68 Transcept Pharmaceuticals 68 Albuferon TM 68 Sign Licensing Agreement 68 Safety Tolerability 68 Interferon beta 1b 68 Anti Angiogenic 68 Therapeutic Vaccine 68 Basal Insulin 68 Clinical Evaluation 68 Ofatumumab 68 Clinically Tested 68 Announce License Agreement 68 BRILINTA 68 FDA Warns Against 68 itraconazole Sporanox 68 Janssen Risperdal 68 LENALIDOMIDE 68 ARIXTRA R 68 Molecular Diagnostic Test 68 alfuzosin 68 Nasal Powder 68 GW# [003] 68 Poster Presentations 68 Non Inferiority 68 Tacrolimus 68 Dose Ranging 68 CYP#A# substrate 68 Protein Involved 68 oral dual endothelin 68 oral renin inhibitor 68 Viagra Soft Cialis Soft 68 Vaccine Adjuvants 68 Demonstrates Long Term 68 #mg/#mg 68 Nasal Sprays 68 Lenocta 68 SABER ™